Reslizumab

BNF:

Not listed

Status:

Red

Decision Date:

December 2016

Comments

RED^1,2,3 : NICE TA479 - for treating severe eosinophilic asthma. (Decision date - November 2017)

NHS England drug. To be used in line with NHS England commissioning intentions

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again